News
| 7 May 2019 |
Result of AGMLONDON, May 07, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that all resolutions proposed at the Annual General Meeting held today wer… |
| 7 May 2019 |
Verona Pharma plc Operational Update and Financial Results for the Three Months Ended March 31, 2019Nebulized ensifentrine as add-on to dual bronchodilator therapy for COPD demonstrated additional increase in lung function on top of maximum current therapy in three-day Phase 2 clinical trial |
| 7 May 2019 |
Verona Pharma Initiates Additional Phase 2b Clinical Trial with Nebulized Ensifentrine to Inform Dose Selection for Phase 3 TrialsLONDON, May 07, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the initiation of a Phase 2b dose-ranging study evaluating nebulized ensif… |
| 7 May 2019 |
Verona Pharma plc Operational Update and Financial Results for the Three Months Ended March 31, 2019Nebulized ensifentrine as add-on to dual bronchodilator therapy for COPD demonstrated additional increase in lung function on top of maximum current therapy in three-day Phase 2 clinical trial |
| 2 May 2019 |
Verona Pharma to Present Clinical Trial Data of Ensifentrine for COPD Maintenance Treatment at American Thoracic Society 2019 International ConferenceLONDON, May 02, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will present data from its chronic obstructive pulmonary disease (… |
| 1 May 2019 |
Verona Pharma to Announce Financial Results for First Quarter Ended March 31, 2019 and Provide Clinical Development UpdateLONDON, May 01, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its audited financial results for the first quarter en… |
| 1 May 2019 |
Verona Pharma plc ("Verona" or the "Company") Appointment of Nominated Adviser and UK BrokerLONDON, May 01, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on respiratory diseases, is pleased to announce the appointment of Nplus1 Singer Advisory LLP (together with i… |
| 25 April 2019 |
Verona Pharma to Host Investor & Analyst R&D Forum in London on May 8, 2019LONDON, April 25, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will host an investor and analyst R&D f… |
| 9 April 2019 |
Verona Pharma Granted Key EU Patent Related to Late-stage COPD Clinical Candidate EnsifentrineLONDON, April 09, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on respiratory diseases, is pleased to announce that the European Patent Office has recently granted an addi… |
| 4 April 2019 |
Grant of Options and RSUs and PDMR DealingsLONDON, April 04, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on April 1, 20… |
Targeting unmet needs
384m people worldwide suffer from COPD and 37 years is the median life expectancy of CF patients
Read more about COPD and CF in the unmet needs section of this website
Basic & Clinical Pharmacology & Toxicology
Peer-reviewed publication on dual PDE3/4 inhibitors as novel treatments for COPD
The Lancet Respiratory Medicine
Peer-reviewed paper in the Lancet's highly-respected medication journal
Verona Pharma plc
3 More London Riverside,
London SE1 2RE
T: +44 (0)203 283 4200
E: info@veronapharma.com
© Verona Pharma plc 2019
